A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia
Clinical trial NCT05232149 · UNKNOWN
Trial details
- NCT number
- NCT05232149
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-21
- Primary completion
- 2023-12-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.